China Heal Plus

HEALTHCARE UPDATE

FDA Grants Accelerated Approval for a Biomarker-Defined Rectal Cancer Treatment

By China Heal Plus · Updated

The FDA granted accelerated approval to dostarlimab (Jemperli) on October 19, 2026 for adults with stage II or III locally advanced rectal cancer classified as MSI-H or dMMR.

A Decision for a Specific Patient Group

These biomarkers describe how a tumor repairs DNA. Eligibility requires an FDA-authorized test. The decision concerns this defined group of patients.

The FDA said partner regulators were still reviewing applications. US approval does not establish access or insurance coverage elsewhere.

Sources: [1]

Preparing for a Specialist Review

For a second-opinion request, organize the pathology and biomarker reports, imaging, and existing treatment plan. Your treating team should assess what the announcement means for your care.

Sources and data notes

  1. FDA: accelerated approval of dostarlimab for locally advanced rectal cancer

    Event October 19, 2026; official announcement and dated approvals index checked October 20. Record-preparation wording is our editorial interpretation. No dosing or response-rate claims republished.

Published by China Heal Plus. General information, not an individual medical assessment. Inclusion of a hospital or physician does not imply a partnership or endorsement of our service.

All healthcare updates